Benralizumab for the Prevention of COPD Exacerbations
Gerard J. Criner(Temple University Hospital), Ubaldo J. Martin(AstraZeneca (Japan)), Bartolomé R. Celli(Brigham and Women's Hospital), Alejandra Ramírez‐Venegas(Instituto Nacional de Enfermedades Respiratorias), Mona Bafadhel(National Institute for Health and Care Research), Natalya Makulova(AstraZeneca (Japan)), Alberto Papi(University of Ferrara), Sean O’Quinn(AstraZeneca (Japan)), Frank C. Sciurba(Pulmonary and Allergy Associates), Don D. Sin(University of British Columbia), Christopher E. Brightling(NIHR Leicester Biomedical Research Centre), Leif Bjermer(Lund University), Àlvar Agustí(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Claus Vogelmeier(German Center for Lung Research), Maria Jison(AstraZeneca (Japan)), Dave Singh(Manchester University NHS Foundation Trust), Paul Newbold(Janssen (United States)), Vibeke Backer(University of Copenhagen), Mitchell Goldman(Amicus Therapeutics (United States)), Vivian H. Shih(AstraZeneca (Japan)), Yu-Feng Wei(E-Da Hospital), Motokazu Kato(Kishiwada City Hospital)
Cited by 329
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
|American Journal of Respiratory and Critical Care Medicine|2017|3.2k
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
|New England Journal of Medicine|2010|3k
American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation
|American Journal of Respiratory and Critical Care Medicine|2006|2k
Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2012|1.3k